Un­sealed doc­u­ments de­tail Bio­gen's fight against San­doz Tysabri biosim­i­lar

San­doz is hop­ing to cel­e­brate its re­cent­ly an­nounced spin­off from No­var­tis with swift ap­provals for its Tysabri biosim­i­lar in both the US and Eu­rope — but not if Bio­gen can help it.

Bio­gen filed suit against San­doz ear­li­er this month, ac­cus­ing the com­pa­ny of at­tempt­ing to “reap the ben­e­fits of Bio­gen’s hard work and suc­cess” by al­leged­ly in­fring­ing on Tysabri’s patent rights.

“Bio­gen has ap­plied for and ob­tained a wide va­ri­ety of is­sued patents cov­er­ing its in­ven­tions re­lat­ing to Tysabri, in­clud­ing re­gard­ing ther­a­peu­tic us­es of Tysabri, ways of mak­ing treat­ment with Tysabri safer for pa­tients and Bio­gen’s in­no­v­a­tive meth­ods of man­u­fac­tur­ing an­ti­bod­ies, such as Tysabri,” the com­pa­ny said in a 107-page redact­ed com­plaint, un­sealed on Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.